LABS-T Medipharm Close 2019-08-12 C$ 6.86 Earns $4.08-million before tax in Q2
MEDIPHARM LABS REPORTS STRONG, PROFITABLE SECOND QUARTER RESULTS
Medipharm Labs Corp. has released its financial results for the three and six months ended June 30, 2019, including strong growth in revenue, EBITDA (earnings before interest, taxes, depreciation and amortization), net income and earnings per share.
KEY Q2 2019 HIGHLIGHTS(2)
Revenue was $31.5 million, a 43% increase over Q1 2019, reflecting the Company's leadership of the Canadian cannabis extraction-only industry and ramp up of new committed contracts
Gross Profit was $11.3 million, a 65% increase over Q1 2019, while Gross Margin was 36% compared to 31% in Q1 2019, reflecting increased production and production efficiency that continues to improve as the Company realizes economies of scale
Adjusted EBITDA(1) was $7.7 million, 79% higher than Q1 2019, while Adjusted EBITDA(1) margin was 24% compared to 20% in Q1 2019
Net income before tax was $4.1 million compared to a net loss of $0.3 million in Q1 2019
Message #63968 from Clark Kent at 7/29/2019 9:06:42 AM
Today will be an interesting lesson --- what happens when a company moves to the TSX?
Closed at $5.46 Friday.
MediPharm Labs Announces Trading Date on the Toronto Stock Exchange 07/25/2019 5:00:00 PM TORONTO, July 25, 2019 (GLOBE NEWSWIRE) --
MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its common shares are expected to begin trading on the Toronto Stock Exchange (“TSX”) on Monday, July 29, 2019 under the symbol “LABS”.
At that time, MediPharm Labs’ common shares will be voluntarily delisted from the TSX Venture Exchange. |
